Sanofi to pay up to $900m to Mannkind for share in insulin Afrezza
Sanofi and Mannkind have signed an exclusive licensing agreement to develop and market the latter’s inhaled insulin diabetes therapy Afrezza. Under the terms of the agreement, France-based Sanofi
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.